Moderna Inc MRNA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD

Last | 1:51 PM EDT

127.99

-0.33 (-0.26%)

Volume

1,558,071

52 week range

62.55 - 142.79

Open127.49
Day High128.47
Day Low124.98
Prev Close128.32
52 Week High142.79
52 Week High Date05/24/23
52 Week Low62.55
52 Week Low Date11/02/23

Key Stats

Market Cap49.051B
Shares Out383.24M
10 Day Average Volume4.50M
Dividend-
Dividend Yield-
Beta1.51
YTD % Change28.93

KEY STATS

Open127.49
Day High128.47
Day Low124.98
Prev Close128.32
52 Week High142.79
52 Week High Date05/24/23
52 Week Low62.55
52 Week Low Date11/02/23
Market Cap49.051B
Shares Out383.24M
10 Day Average Volume4.50M
Dividend-
Dividend Yield-
Beta1.51
YTD % Change28.93

RATIOS/PROFITABILITY

EPS (TTM)-15.66
P/E (TTM)-8.17
Fwd P/E (NTM)-16.54
EBITDA (TTM)-4.559B
ROE (TTM)-37.68%
Revenue (TTM)5.153B
Gross Margin (TTM)22.43%
Net Margin (TTM)-115.82%
Debt To Equity (MRQ)4.49%

EVENTS

Earnings Date08/01/2024(est)
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Latest On Moderna Inc

Lightning Round: Hertz is too cheap right now, says Jim Cramer18 Hours AgoCNBC.com
Cramer's Lightning Round: 'I'm a believer' in Moderna19 Hours AgoCNBC.com
Evercore ISI sees an end to 3 years of biotech underperformance, gives 5 top stocksMay 14, 2024CNBC.com
8. ElevateBioMay 14, 2024CNBC.com
Novavax stock jumps 50% as Sanofi vaccine deal kicks off a turnaroundMay 13, 2024CNBC.com

Content From Our Affiliates

Early notable gainers among liquid option names on May 13thMay 13, 2024TipRanks
Moderna says FDA does not expect to complete mRNA-1345 BLA review by May 12May 10, 2024TipRanks
Moderna (MRNA) Receives a Buy from JefferiesMay 9, 2024TipRanks
Moderna price target raised to $135 from $125 at RBC CapitalMay 3, 2024TipRanks
Moderna price target raised to $155 from $125 at JefferiesMay 3, 2024TipRanks

Profile

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the...

Noubar Afeyan Ph.D.

Non-Executive Independent Chairman of the Board, Co-Founder

Stephane Bancel

Chief Executive Officer, Director

Stephen Hoge M.D.

President

Jerh Collins

Chief Technical Operations and Quality Officer

James Mock

Chief Financial Officer

Brad Miller

Chief Information Officer

Address

325 BINNEY STREET

Cambridge, MA

02142

United States

https://www.modernatx.com/

Top Peers

SYMBOL	LAST	CHG	%CHG
ILMN Illumina Inc	114.21	-1.37	-1.19%
BIIB Biogen Inc	236.02	+9.14	+4.03%
BNTX Biontech SE	92.39	+0.11	+0.12%
CRL Charles River Laboratories International Inc	235.14	+2.32	+1.00%
GMAB Genmab A/S	30.29	+0.75	+2.56%